BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33451103)

  • 1. FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells.
    Ghatak S; Hascall VC; Markwald RR; Misra S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells.
    Oh PS; Patel VB; Sanders MA; Kanwar SS; Yu Y; Nautiyal J; Patel BB; Majumdar AP
    Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G347-55. PubMed ID: 21596996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through
    Ghatak S; Hascall VC; Karamanos N; Markwald RR; Misra S
    Front Oncol; 2022; 12():906260. PubMed ID: 36330477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.
    Fan CW; Chen T; Shang YN; Gu YZ; Zhang SL; Lu R; OuYang SR; Zhou X; Li Y; Meng WT; Hu JK; Lu Y; Sun XF; Bu H; Zhou ZG; Mo XM
    Cell Death Dis; 2013 Oct; 4(10):e828. PubMed ID: 24091671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay Between Chemotherapy-Activated Cancer Associated Fibroblasts and Cancer Initiating Cells Expressing CD44v6 Promotes Colon Cancer Resistance.
    Ghatak S; Hascall VC; Karamanos N; Markwald RR; Misra S
    Front Oncol; 2022; 12():906415. PubMed ID: 35982950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of the transcription factor YB-1 for maintaining the stemness of cancer stem cells and reverting differentiated cancer cells into cancer stem cells.
    Yang F; Cui P; Lu Y; Zhang X
    Stem Cell Res Ther; 2019 Aug; 10(1):233. PubMed ID: 31375149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
    Cheng W; Liu T; Wan X; Gao Y; Wang H
    FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
    Barkeer S; Chugh S; Karmakar S; Kaushik G; Rauth S; Rachagani S; Batra SK; Ponnusamy MP
    BMC Cancer; 2018 Nov; 18(1):1157. PubMed ID: 30466404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway.
    Wang X; Wang R; Bai S; Xiong S; Li Y; Liu M; Zhao Z; Wang Y; Zhao Y; Chen W; Billiar TR; Cheng B
    J Exp Clin Cancer Res; 2019 Dec; 38(1):505. PubMed ID: 31888685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the thyroid hormone T3 and its nuclear receptor TRĪ±1 on colon cancer stem cell phenotypes and response to chemotherapies.
    Giolito MV; Bodoirat S; La Rosa T; Reslinger M; Guardia GDA; Mourtada J; Claret L; Joung A; Galante PAF; Penalva LOF; Plateroti M
    Cell Death Dis; 2024 May; 15(5):306. PubMed ID: 38693105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil.
    Nandi SK; Roychowdhury T; Chattopadhyay S; Basu S; Chatterjee K; Choudhury P; Banerjee N; Saha P; Mukhopadhyay S; Mukhopadhyay A; Bhattacharya R
    Toxicol Appl Pharmacol; 2022 Feb; 437():115887. PubMed ID: 35063459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silibinin, A Natural Blend In Polytherapy Formulation For Targeting Cd44v6 Expressing Colon Cancer Stem Cells.
    Patel S; Waghela B; Shah K; Vaidya F; Mirza S; Patel S; Pathak C; Rawal R
    Sci Rep; 2018 Nov; 8(1):16985. PubMed ID: 30451890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a subpopulation of long-term tumor-initiating cells in colon cancer.
    Peng L; Xiong Y; Wang R; Xiang L; Zhou H; Gu H
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE.
    Misra S; Hascall VC; De Giovanni C; Markwald RR; Ghatak S
    J Biol Chem; 2009 May; 284(18):12432-46. PubMed ID: 19246453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.
    Tsofack SP; Garand C; Sereduk C; Chow D; Aziz M; Guay D; Yin HH; Lebel M
    Mol Cancer; 2011 Nov; 10():145. PubMed ID: 22118625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
    To K; Fotovati A; Reipas KM; Law JH; Hu K; Wang J; Astanehe A; Davies AH; Lee L; Stratford AL; Raouf A; Johnson P; Berquin IM; Royer HD; Eaves CJ; Dunn SE
    Cancer Res; 2010 Apr; 70(7):2840-51. PubMed ID: 20332234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knock out CD44 in reprogrammed liver cancer cell C3A increases CSCs stemness and promotes differentiation.
    Han S; Guo J; Liu Y; Zhang Z; He Q; Li P; Zhang M; Sun H; Li R; Li Y; Zeng W; Liu J; Lian L; Gao Y; Shen L
    Oncotarget; 2015 Dec; 6(42):44452-65. PubMed ID: 26540347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.
    Lv L; Liu HG; Dong SY; Yang F; Wang QX; Guo GL; Pan YF; Zhang XH
    Tumour Biol; 2016 Jul; 37(7):8811-24. PubMed ID: 26747179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction between PDCD4 and YB1 is critical for cervical cancer stemness and cisplatin resistance.
    Liu D; Ke J; Liu Y; Rao H; Tang Z; Liu Y; Zhang Z; You L; Luo X; Sun Z; He Z; Li F; Qiu Z; Hu J; Mbadhi MN; Tang J; Wu F; Li S
    Mol Carcinog; 2021 Dec; 60(12):813-825. PubMed ID: 34499772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.